Standard prophylactic versus intermediate dose enoxaparin in adults with severe COVID-19: A multi-center, open-label, randomized controlled trial.

Usha S PerepuIsaac ChambersAbdul WahabPatrick Ten EyckChaorong WuSanjana DayalGrerk SutamtewagulSteven R BaileyLori J RosensteinSteven R Lentz

Published in: Journal of thrombosis and haemostasis : JTH (2021)

In hospitalized adults with severe COVID-19, standard prophylactic dose and intermediate dose enoxaparin did not differ significantly in preventing death or thrombosis at 30 days.

Keyphrases

coronavirus disease
randomized controlled trial
sars cov
venous thromboembolism
open label
study protocol
early onset
pulmonary embolism
squamous cell carcinoma
drug induced
systematic review
rectal cancer